Johnson & Johnson: Lupus Erythematosus, Systemic trials

The registry lists 10 Lupus Erythematosus, Systemic studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 2Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusRecruitingNCT07438496Phase 3
• A Study of Ustekinumab in Participants With Active Systemic Lupus ErythematosusTerminatedNCT03517722Phase 3Results posted
• A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus ErythematosusCompletedNCT02349061Phase 2Results posted
• A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT04882878Phase 2
• A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus ErythematosusWithdrawnNCT04060888Phase 3
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus ErythematosusWithdrawnNCT02920424Phase 1
• A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus ErythematosusCompletedNCT02609789Phase 1
• A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy VolunteersCompletedNCT02034344
• A Non-drug Study Profiling Cutaneous LupusCompletedNCT01923415
• A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus ErythematosusCompletedNCT01702740Phase 1